Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) Injection in the Management of Superficial Lipomas

NARecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

March 20, 2026

Study Completion Date

June 20, 2026

Conditions
Lipoma
Interventions
DEVICE

Embella (Deoxycholic acid, produced by Espad Pharmed Co.)

0.1 mL or 0.15 mL of a 10 mg/mL deoxycholic acid solution will be injected into every 1\*1 cm2 of the lipoma using an insulin syringe with a 1cm needle attached (the max volume of injection is 2 cc in each treatment session).

Trial Locations (2)

19947-66411

COMPLETED

Orchid Pharmed, Medical Department, Tehran

Unknown

RECRUITING

Razi hospital, Tehran

All Listed Sponsors
lead

Espad Pharmed

INDUSTRY